MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1
Cancer Cell International,
Abstract Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in…
Abstract Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in…
Follow Summary Relay Therapeutics is a biotech company focused on developing small molecule inhibitors for cancer treatment.
GlobeNewswire 2023-10-16 MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-Americ…
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…